Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

The diagnosis and management of soft tissue knee injuries: internal derangements.

BIBLIOGRAPHIC SOURCE(S)

  • New Zealand Guidelines Group (NZGG). The diagnosis and management of soft tissue knee injuries: internal derangements. Wellington (NZ): New Zealand Guidelines Group (NZGG); 2003 Jul. 100 p. [229 references]

GUIDELINE STATUS

This is the current release of the guideline.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory information has been released.

On April 7, 2005, after concluding that the overall risk versus benefit profile is unfavorable, the FDA requested that Pfizer, Inc voluntarily withdraw Bextra (valdecoxib) from the market. The FDA also asked manufacturers of all marketed prescription nonsteroidal anti-inflammatory drugs (NSAIDs), including Celebrex (celecoxib), a COX-2 selective NSAID, to revise the labeling (package insert) for their products to include a boxed warning and a Medication Guide. Finally, FDA asked manufacturers of non-prescription (over the counter [OTC]) NSAIDs to revise their labeling to include more specific information about the potential gastrointestinal (GI) and cardiovascular (CV) risks, and information to assist consumers in the safe use of the drug. See the FDA Web site for more information.

Subsequently, on June 15, 2005, the FDA requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products. FDA recommended proposed labeling for both the prescription and over-the-counter (OTC) NSAIDs and a medication guide for the entire class of prescription products. All sponsors of marketed prescription NSAIDs, including Celebrex (celecoxib), a COX-2 selective NSAID, have been asked to revise the labeling (package insert) for their products to include a boxed warning, highlighting the potential for increased risk of cardiovascular (CV) events and the well described, serious, potential life-threatening gastrointestinal (GI) bleeding associated with their use. FDA regulation 21CFR 208 requires a Medication Guide to be provided with each prescription that is dispensed for products that FDA determines pose a serious and significant public health concern. See the FDA Web site for more information.

BRIEF SUMMARY CONTENT

 ** REGULATORY ALERT **
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Definitions for the Grades of Recommendation (A-C, & I) and Level of Evidence (1-4) are given at the end of the "Major Recommendations" field.

Diagnosis

Excluding Fractures

A The Ottawa Knee Rules should be applied in the evaluation of acute knee injuries to assist clinicians in making decisions about the need for radiography to exclude fractures.

C People with a haemarthrosis should be x-rayed to exclude fractures.

C People with significant fractures should be referred immediately to an orthopaedic surgeon. For people with a minor undisplaced fracture, orthopaedic surgeons need to review the films only.

C The routine use of x-rays is generally not recommended.

Initial Management and Referral

C People with no evidence of ligament laxity or meniscal damage should be treated with R.I.C.E. (rest, ice, compression, elevation) and paracetamol, if required, and advised to resume usual activities when pain and swelling have settled, and return for follow-up if symptoms persist after 7 days.

C Urgent referral to an orthopaedic surgeon is required for people with:

  • red flag signs and symptoms (see original guideline document for "Red Flags")
  • severe knee injuries
  • significant fracture on x-ray

C Early referral to a specialist is recommended for people with:

  • injury to the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), or posterolateral complex
  • a locked knee due to suspected meniscal entrapment
  • equivocal diagnosis

C Subsequent referral to a specialist for people:

  • with a suspected meniscal tear if symptoms persist after a trial of rehabilitation for 6 to 8 weeks
  • at any stage of the rehabilitation process where symptoms persist and clinical milestones are not being achieved

C Referral for rehabilitation is recommended for people with:

  • suspected meniscal tears
  • injuries to the medial collateral ligament (MCL)
  • other ligament injuries to manage symptoms until seen by a specialist

Imaging

C Magnetic resonance imaging (MRI) may be considered by specialists where further information is required to make a diagnosis and decide appropriate subsequent management.

Clinical Evaluation

Medial Collateral Ligament

C A positive valgus stress test performed in extension and 30 degrees of flexion is reasonably accurate in the diagnosis of an MCL tear.

C Tenderness along the course of the MCL is suggestive of MCL injury.

Medial and Lateral Meniscus

C In the context of an appropriate history the McMurray test, well localised joint line tenderness, and a block to end range extension may have some additional diagnostic significance.

Anterior Cruciate Ligament

A The Lachman test when correctly performed is reasonably accurate in the diagnosis of complete ruptures of the ACL.

B The Lachman test is more accurate when acute pain, swelling, and muscle spasm have subsided at about 10 days.

C The pivot shift test is best performed by experienced practitioners.

C Loss of end range extension should alert the clinician to the possible involvement of the ACL.

Posterior Cruciate Ligament

C The posterior drawer test is the most sensitive test for evaluating the integrity of the PCL.

Posterolateral Complex

C Primary care providers should refer any people with suspected injury of the posterolateral complex to an orthopaedic surgeon for further evaluation.

General Management

R.I.C.E (Rest, Ice, Compression, Elevation)

C There is insufficient evidence in the literature to support the use of R.I.C.E.; however, it is commonly accepted practice for the self-management of a mild soft tissue knee injury in the first 48 to 72 hours. Refer to the original guideline document for R.I.C.E. protocol.

Pharmacology

C Paracetamol is probably the most cost-effective and potentially least harmful choice of analgesic for soft tissue knee injuries.

C Nonsteroidal anti-inflammatory drugs (NSAIDs) may be beneficial for treating a persistent effusion that has not responded to the R.I.C.E. protocol.

A Topical NSAIDs are effective and safe for acute sprains, strains, and sports injuries.

Haemarthrosis

C Aspiration is not generally indicated for diagnosis.

C Aspiration is indicated for a severe and painful suspected haemarthrosis of the knee joint following an acute knee injury.

C For practitioners who are not experienced in the procedure, people should be treated with usual R.I.C.E. and referred to a specialist, local Base Hospital, or another practitioner who has more experience.

Rehabilitation

Physiotherapy

A There is insufficient evidence in the literature to establish the relative effectiveness of the various approaches and methods currently used by physiotherapists in the conservative management of soft tissue knee injuries.

B Proprioceptive training may be beneficial in improving outcomes for people with ACL-deficient knees, and its inclusion in rehabilitation programmes for both the conservative and post-operative management of ACL tears is recommended.

Electrotherapy Modalities

B Ultrasound is of little benefit in the treatment of soft tissue knee injuries.

I At present there is insufficient evidence to support the use of neuromuscular electrical stimulation (NMES), transcutaneous electric nerve stimulation (TENS), or biofeedback in the post-operative rehabilitation following meniscectomy or ACL reconstruction.

Bracing in the Non-operative Management of Knee Injuries

I Bracing is generally not required for the conservative management of soft tissue knee injuries.

C Bracing is appropriate for isolated Grade III and severe Grade II injuries to the MCL for 4 to 6 weeks to stabilise the knee so that rehabilitation can be initiated.

C Bracing may be indicated in selected cases where recurrent instability exists, but concurrent medical conditions or other factors preclude surgery.

C Bracing may be indicated in selected cases where there is a psychological benefit associated with wearing a brace which enhances a person’s ability to undertake tasks in work and sport.

Osteopathy, Chiropractic and Acupuncture

I No recommendations can be made about the use of acupuncture, chiropractic, osteopathy, or other complementary therapies for the treatment of soft tissue knee injuries due to a lack of good quality evidence.

Specific Management

Operative Versus Non-operative

C Non-operative management is recommended for all grades of isolated medial collateral ligament injuries.

Anterior Cruciate Ligament

C In general, ACL reconstruction has the most to offer those people with recurrent instability who must perform multidirectional activity as part of their occupation or sport.

C Age should not be considered a barrier to reconstructive surgery in the older athlete, providing there are appropriate indications.

C An active functional treatment programme supervised by a physiotherapist is recommended following ACL reconstruction.

B Open kinetic chain exercises can be introduced from 4 to 6 weeks between 90 and 45 degrees of knee flexion.

B Bracing in the immediate post-operative period following ACL reconstruction is not recommended.

Medial and Lateral Meniscus

A Physiotherapy is not routinely advocated following meniscectomy.

Posterior Cruciate Ligament

C There is general agreement that Grade I and II isolated PCL tears are best managed nonoperatively.

I There is insufficient evidence to establish the relative benefits of operative versus nonoperative management of isolated Grade III PCL tears.

C Practitioners should follow the post-operative rehabilitation protocol recommended by the orthopaedic surgeon.

Posterolateral Complex

C Practitioners should follow the protocol recommended by the orthopaedic surgeon.

Special Groups

C Health practitioners providing care for Maori and Pacific Island peoples should be sensitive to their particular needs and encourage the use of a support person or advocate.

Definitions

Grades of Recommendations

A

The recommendation is supported by good evidence.

B

The recommendation is supported by fair evidence.

C

The recommendation is supported by expert opinion only, based on level 4 evidence in the text and the expertise within the multidisciplinary team.

I

No recommendation can be made because the evidence is insufficient (i.e., evidence is lacking, of poor quality or conflicting and the balance of benefits and harms cannot be determined).

Level of Evidence

1++

High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias

1+

Well conducted meta-analysis, systematic reviews of RCTs, or RCTs with a low risk of bias

1-

Well conducted meta-analysis, systematic reviews of RCTs, or RCTs with a high risk of bias

2++

High quality systematic review or case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.

2+

Well conducted case-control of cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.

2-

Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal

3

Non-analytic studies (e.g., case reports, case series)

4

Expert Opinion (e.g., narrative reviews)

CLINICAL ALGORITHM(S)

The original guideline document provides clinical algorithms for the diagnosis and management of soft tissue knee injuries.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The advice on the management of internal derangements of the knee given in this guideline is based on epidemiological and other research evidence, supplemented where necessary by the consensus opinion of the expert development team based on their own experience.

Only systematic reviews, meta-analyses, randomised controlled trials, or quasi-randomised controlled trials were considered for inclusion for the guideline. Observational studies, case studies, and laboratory base studies were excluded.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • New Zealand Guidelines Group (NZGG). The diagnosis and management of soft tissue knee injuries: internal derangements. Wellington (NZ): New Zealand Guidelines Group (NZGG); 2003 Jul. 100 p. [229 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2003 Jul

GUIDELINE DEVELOPER(S)

New Zealand Guidelines Group - Private Nonprofit Organization

SOURCE(S) OF FUNDING

The Accident Compensation Corporation (ACC)

GUIDELINE COMMITTEE

Effective Practice, Informatics and Quality Improvement (EPIQ) Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Guideline Team Members: Bruce Arroll, MBChB PhD, FRNZCGP, FAFPHM, Associate Professor (Chair); Gillian Robb, MPH (Hons) Dip Physiotherapy Dip Ergonomics, Dip MT (Project Manager); Emma Sutich, MA(Appl) Clin & Comm Psych (NZGG Project Manager)

Diagnostic Team Members: Sunia Foliaki, MBBS (PNG); M Tropical Health (Aust), MPH (USA), Public Health Consultant, Representing a Pacific perspective; Peter Gendall, MB ChB FRANZCR, Musculoskeletal Radiologist; Chris Milne, MBChB; Dip Sports Medicine, FRNZCGP; FACSP, Sports Physician, Hamilton, National Chairman Sports Medicine NZ, Medical Director, Northern Region, NZ Academy of Sport; Graeme Moginie, Adv Dip Physiotherapy; Dip MT, NZ Registered Physiotherapist, Acupuncture, Physiotherapist, Dunedin; Jolene Phillips, Administration Assistant Arthritis NZ, Representing a consumer perspective, Wellington; Rocco Pitto, MD, PhD, Associate Professor, Consultant Orthopaedic Surgeon, University of Auckland, Middlemore Hospital; Rachel Thomson, MBChB, GP Hamilton, Representing a Maori perspective; Russell Tregonning, MBChB; FRACS FNZOA, Orthopaedic and Knee Surgeon, Wellington; James Watt, MBChB; MRCP (UK) FRNZCGP; FAFMM; Dip MSM; Dip Obst Musculoskeletal Specialist, Auckland

Treatment Team Members: Russell Blakelock, BHB; MBChB, FRACS (General & Paediatric Surgery), Representing a Pacific perspective, Consultant Paediatric Surgeon, Christchurch Hospital; John Matheson, MBChB; MSc (Oxon) FRACS, Orthopaedic Surgeon, Dunedin President NZ Knee Society; Neil Matson, BSc; MBChB; Dip Obst; Dip Sports Medicine; FRNZCGP General Practitioner, Tauranga; Peter McNair, PhD MNZCP, Director of the Physical Rehabilitation Research Centre, Auckland University of Technology, Professor of Physiotherapy; Ian Murphy MBChB; PG Diploma Sports Med, Sports Medicine Registrar, Auckland; Peter Pfitzinger BSc; MSc; MBA, Representing a consumer perspective; Paul Quin, MBChB; Dip MSM (Otago) FAFMM, Musculoskeletal Specialist, Auckland; Keri Ratima, MBChB; MMed Sci; FRNZCGP, Representing a Maori perspective, GP Wellington; Duncan Reid, BSc; MHSc; PGD (Manip Physio); Dip MT Dip, Physiotherapy, Senior Lecturer, Physiotherapy, AUT Auckland; Barry Tietjens, MBChB (Otago) MSc (Oxon) FRCS (Ed) FRACS, Orthopaedic Surgeon, Auckland

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Members of the guideline team who are in clinical practice receive payments from the Accident Compensation Corporation (ACC) for the diagnosis and management of ACC claimants with knee injuries. This is not considered a competing interest.

John Matheson is involved with the Highlanders' Franchise.

Peter McNair undertakes educational talks and seminars for Workscience Ltd and sells equipment used for the rehabilitation of muscles following injury.

Peter Gendall is a minority shareholder in Manukau Radiology Institute Ltd and in Mercy MRI Ltd. He is also an employee of Mercy Radiology Group and a contractor to Manukau Radiology Institute Ltd.

Russell Tregonning has received funding from Zimmer (NZ) and Bionet (NZ) for attendance at symposiums.

No other competing interests were declared.

ENDORSER(S)

Arthritis New Zealand - Medical Specialty Society
Effective Practice, Informatics & Quality Improvement (New Zealand) - Professional Association
New Zealand Orthopaedic Association - Professional Association
New Zealand Society of Physiotherapists - Professional Association
NZ Association of Musculoskeletal Medicine - Medical Specialty Society
Royal Australian and New Zealand College of Radiologists - Professional Association
Royal New Zealand College of General Practitioners - Medical Specialty Society
Sports Medicine New Zealand - Professional Association

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the New Zealand Guidelines Group Web site.

Print copies: Available from the New Zealand Guidelines Group Inc., Level 10, 40 Mercer Street, PO Box 10 665, The Terrace, Wellington, New Zealand; Tel: 64 4 471 4180; Fax: 64 4 471 4185; e-mail: info@nzgg.org.nz

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Print copies: Available from the New Zealand Guidelines Group Inc., Level 10, 40 Mercer Street, PO Box 10 665, The Terrace, Wellington, New Zealand; Tel: 64 4 471 4180; Fax: 64 4 471 4185; e-mail: info@nzgg.org.nz

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on June 16, 2004. The information was verified by the guideline developer on July 19, 2004. This summary was updated on May 3, 2005 following the withdrawal of Bextra (valdecoxib) from the market and the release of heightened warnings for Celebrex (celecoxib) and other nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). This summary was updated by ECRI on June 16, 2005, following the U.S. Food and Drug Administration advisory on COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs).

COPYRIGHT STATEMENT

These guidelines are copyrighted by the New Zealand Guidelines Group. They may be downloaded and printed for personal use or for producing local protocols in New Zealand. Re-publication or adaptation of these guidelines in any form requires specific permission from the Chief Executive of the New Zealand Guidelines Group.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo